Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• This summary is based on the review of two randomized controlled trial(s). ^[1-2]
• In the MagnetisMM-3 phase 2 trial, elranatamab showed an objective response rate (ORR) of 61.0% in B-cell Maturation Antigen (BCMA)-naive patients, with 35.0% achieving a complete response or better. Median duration of response, progression-free survival, and overall survival rates at 15 months were 71.5%, 50.9%, and 56.7%, respectively, with a median follow-up of 14.7 months.
• Early improvements in patient-reported outcomes (PROS) were observed, with 40.2% of BCMA-naive and 52.6% of BCMA-exposed patients reporting their disease as 'a little better' or 'much better' by Cycle 1, Day 15.
• In the MagnetisMM-3 trial, common adverse events in patients receiving elranatamab included infections (69.9%, with 39.8% being grade 3-4), cytokine release syndrome (57.7%, with no grade 3-4 events), anemia (48.8%, with 37.4% being grade 3-4), and neutropenia (48.8%, with 48.8% being grade 3-4).
• Switching patients to biweekly dosing after six treatment cycles reduced the rate of grade 3-4 adverse events from 58.6% to 46.6%, indicating improved safety outcomes without compromising treatment efficacy.
• The MagnetisMM-3 trial showed that elranatamab was effective in both BCMA-naive and BCMA-exposed patients with relapsed or refractory multiple myeloma, with improvements in PROS observed as early as Cycle 1, Day 15. The objective response rate was 61% in BCMA-naive patients, with 35% achieving a complete response or better. Additionally, a subgroup of responders who transitioned to biweekly dosing after six cycles experienced improved safety outcomes without compromising efficacy.